Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLI1100 in moderate to severe acne vulgaris
NCT01815450Phase 2Completed
- Sponsor
- Braintree Laboratories
- Start
- Feb 2013
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BLI1100 in acne vulgaris (3 arms), sponsored by Braintree Laboratories. Primary endpoint: Change in total lesion count at 12 weeks. Started Feb 2013; status: completed.
02
Drugs
BLI1100
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT01815450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815450.